Get the Stockscreener App
4.365
0.93%
0.045
Lumos Pharma Inc stock is traded at $4.365, with a volume of 187.16K.
It is up +0.93% in the last 24 hours and up +16.89% over the past month.
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.
See More
Previous Close:
$4.32
Open:
$4.32
24h Volume:
187.16K
Relative Volume:
2.11
Market Cap:
$37.45M
Revenue:
$2.74M
Net Income/Loss:
$-41.38M
P/E Ratio:
-0.9268
EPS:
-4.71
Net Cash Flow:
$-31.10M
1W Performance:
+0.69%
1M Performance:
+16.89%
6M Performance:
+73.02%
1Y Performance:
+42.95%
1-Day Range:
$4.31
$4.37
1-Week Range:
$4.30
$4.39
52-Week Range:
$1.3701
$4.5756
Lumos Pharma Inc Stock (LUMO) Company Profile
Name
Lumos Pharma Inc
Sector
Industry
Phone
512-215-2630
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare LUMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| LUMO | 4.345 | 37.45M | 2.74M | -41.38M | -31.10M | -4.71 |
| VRTX | 447.42 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.52 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.60 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.15 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.88 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Lumos Pharma Inc Stock (LUMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-21 | Upgrade | Stifel | Hold → Buy |
| Dec-03-20 | Initiated | Cantor Fitzgerald | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-17-20 | Resumed | ROTH Capital | Buy |
| Aug-04-20 | Initiated | H.C. Wainwright | Buy |
Lumos Pharma Inc Stock (LUMO) Latest News
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 - GlobeNewswire
Lumos Pharma Faces Uncertainty as CVRs Risk Expiring Worthless Post-Merger - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, OB on Behalf of Shareholders - GlobeNewswire
Private Advisor Group, LLC Acquires Shares in Lumos Pharma Inc - GuruFocus.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ALTR, STAF on Behalf of Shareholders - Marketscreener.com
Finansavisen - Finansavisen
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Reviews the Merger of STAF, ATSG, GABC and LUMO - AccessWire
$HAREHOLDER ALERT FOR STAF, ATSG, GABC and ALTM: The M&A Class Action Firm Continues to Investigate the Merger - AccessWire
Lumos: Q3 Earnings Snapshot - CT Insider
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, INSI on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO - GlobeNewswire Inc.
Peregrine Gold Ltd Confirms Prospectus Lodgement for Security Issue - MSN
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024 - The Manila Times
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, BMTX, NXU on Behalf of Shareholders - cnhinews.com
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Discover Smart Share Global Among 2 Other Prominent US Penny Stocks - Simply Wall St
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ZUO, ARC on Behalf of Shareholders - Stockhouse Publishing
Analyst Expectations For Lumos Pharma's Future - Benzinga
INVESTIGATION ALERT: Halper Sadeh LLC Continues to - GlobeNewswire
Kuehn Law Encourages MMLP, ICCH, FSHP, and LUMO Investors to Contact Law Firm - Morningstar
DPV set to acquire Lumos Pharma for $38m - Pharmaceutical Technology
Lumos Pharma to be acquired by Double Point Ventures - Investing.com Canada
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc. - Marketscreener.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders - Longview News-Journal
Jones Trading cuts Lumos Pharma shares rating amid Double Point merger - Investing.com UK
Lumos inks take-private deal with Double Point Ventures - MSN
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders - Business Wire
Lumos Pharma Shares Rally After Double Point Deal - MarketWatch
Shareholder Alert: Ademi LLP Investigates Whether Lumos Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) - The Manila Times
Lumos stock in focus after take-private deal (LUMO:NASDAQ) - Seeking Alpha
Double Point to Buy Lumos Pharma for $38M as FDA OKs Lumos Drug Trial - MarketWatch
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, USAP, SASR on Behalf of Shareholders - cnhinews.com
Hypopituitarism Market Forecasted to Surge in Coming Years, - openPR
Lumos Pharma Inc (LUMO) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Prudence - Investing.com Canada
Proactive financial news: fast, accessible, and actionable articles and videos for the global investment audience. - Proactive Investors USA
Lumos Pharma maintains target with Buy rating by H.C. Wainwright - Investing.com Canada
Lumos Pharma (NASDAQ:LUMO) Rating Reiterated by HC Wainwright - Defense World
Clene (NASDAQ:CLNN) Stock Quotes, Forecast and News Summary - Benzinga
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024 - ForexTV.com
Apple's iPhone 16 lead times track below past three cycles: MS - Head Topics
You might want to take a look at Lumen Technologies Inc (LUMN) now - SETE News
Stocks of Lexicon Pharmaceuticals Inc (LXRX) are poised to climb above their peers - SETE News
Lumen Technologies (NYSE:LUMN) Trading Down 2.9% - MarketBeat
Caxton Associates LP Increases Stock Holdings in Lululemon Athletica Inc. (NASDAQ:LULU) - Defense World
Lufax Holding Ltd ADR [LU] Revenue clocked in at $3.82 billion, up 83.43% YTD: What’s Next? - The DBT News
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Lululemon Athletica Inc.LULU - PR Newswire
Oct. 7th Deadline Alert: Investors Who Lost More Than $100,000 With Lululemon Athletica Inc. (NASDAQ: LULU) Shares Should Contact the Shareholders Foundation - Newswire
Analytical Overview: Lumen Technologies Inc (LUMN)’s Ratios Tell a Financial Story - The Dwinnex
LB Aluminium's 1Q profit doubles as revenue hits highest in two decades - The Edge Malaysia
Lumen Technologies Inc (NYSE: LUMN) – An Analysis Is What You Need - Stocks Register
Lumos Pharma Inc Stock (LUMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lumos Pharma Inc Stock (LUMO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McKew John C. | Chief Scientific Officer |
Apr 03 '24 |
Sale |
2.77 |
2,214 |
6,144 |
17,153 |
| McKew John C. | Chief Scientific Officer |
Feb 06 '24 |
Sale |
3.03 |
438 |
1,328 |
18,403 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):